(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
(177)Lu-PSMA-617 与更换雄激素受体通路抑制剂治疗既往未接受过紫杉烷类药物治疗的进展性转移性去势抵抗性前列腺癌患者的疗效比较 (PSMAfore):一项 3 期随机对照试验
期刊:Lancet
影响因子:88.5
doi:10.1016/S0140-6736(24)01653-2
Morris, Michael J; Castellano, Daniel; Herrmann, Ken; de Bono, Johann S; Shore, Neal D; Chi, Kim N; Crosby, Michael; Piulats, Josep M; Fléchon, Aude; Wei, Xiao X; Mahammedi, Hakim; Roubaud, Guilhem; Študentová, Hana; Nagarajah, James; Mellado, Begoña; Montesa-Pino, Álvaro; Kpamegan, Euloge; Ghebremariam, Samson; Kreisl, Teri N; Wilke, Celine; Lehnhoff, Katja; Sartor, Oliver; Fizazi, Karim